Defibrotide Dose-escalation for SOS Post-HSCT
Study Details
Study Description
Brief Summary
This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Defibrotide 7.1.1 HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought (see 7.2 for definition of response) (Maximum of 4 dose levels) (7.1.2): |
Drug: Defibrotide
HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To determine the incidence of grade 3 or 4 adverse events related to defibrotide [100 days]
grade 3 and 4 adverse events possible or probably related to defibrotide will be collected
Eligibility Criteria
Criteria
Inclusion Criteria:
-
HCT recipients (Auto or Allograft)
-
SOS/VOD as defined by Cairo/Cooke Diagnostic criteria (1) (Table 3) with either renal and/or pulmonary dysfunction as defined by Cairo/Cooke Grading criteria (1) (Appendix I).
-
Unresponsive to standard defibrotide therapy as defined by at least one of the following:
-
Patients with SOS/VOD failing to obtain a complete response (CR) defined by Grade I or less by Cairo/Cooke Grading criteria (1) (Appendix I). This would therefore include patients with stable disease after at least 14 days of defibrotide or partial response after at least 21 days of defibrotide (25mg/kg/day).
-
Progressive disease defined by progression of at least one grade or more from diagnostic grade as defined by Cairo/Cooke Grading criteria (1) (Appendix I) following at least 7 days of defibrotide (25mg/kg/day).
-
Age 1 month - 75 years
Exclusion Criteria:
-
Patients who did not receive HCT.
-
Concomitant systemic anticoagulation (excluding central venous line management, fibrinolytic instillation for central venous line occlusion, management of intermittent dialysis or ultrafiltration of CVVH).
-
Active bleeding and/or hemorrhage of at least grade 2 and above.
-
History of development of Grade III/IV anaphylaxis probably or directly secondary to defibrotide.
-
Female patients who are pregnant or breast feeding.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- New York Medical College
Investigators
- Principal Investigator: Mitchell Cairo, MD, New York Medical College
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NYMC 600